This is a working overview of actin binding, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-01. Anything still debated is marked as such rather than presented as settled.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
| Property | Value | Notes |
|---|---|---|
| Analytical method | LC-MS/MS | Preferred confirmatory technique |
| Appearance | White to off-white powder | Lyophilised form |
| Solubility | Freely soluble in water | Also described in saline |
| Storage temperature | Below -20 °C for powder | Short-term refrigeration for solutions |
| Regulatory status | Prohibited in sport | Listed under peptide hormones |
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
In practice, existing TA units found themselves stripped of regular training staffs and often many of their own officers and NCOs to form and train the new units, long before their own units were fully trained. As a result, some TA divisions had made little progress by the time the Second World War began; others, who had started from a stronger position, were able to complete this work within a matter of weeks.
The chestnut or sorrel color, genetically considered "red", is caused by one of two recessive alleles at the extension locus (genetics). Extension has three known alleles: the wildtype "E", necessary for the bay and black coat colors, plus two mutations "e" and "ea", both of which are capable of causing the chestnut color. Each individual horse has two copies of the extension gene. If either copy is "E", then the horse will be bay- or black-based. But if the two copies are any combination of "e" and "ea" (e/e, e/ea, or ea/ea), then the horse will be red-based. Alternate extension "ea" is rare and there is no known difference in appearance between it and the more common "e". Because the red color is recessive, two bay or black parents can produce a chestnut foal if both carry "e" or "ea". However, two chestnut parents cannot produce a bay or black foal. The extension locus (genetics) is found on chromosome 3 (ECA3) and is part of the gene that codes for the equine melanocortin 1 receptor (MC1R). This receptor is part of a signalling pathway which when activated causes melanocytes to produce eumelanin, or black pigment, instead of pheomelanin, or red pigment. The two mutant alleles "e" and "ea" code for dysfunctional receptors unable to activate this pathway, so absent "E", only red pigment can be produced. At least one copy of the functional "E" allele is required to activate the signal and produce black pigment.
=== Refractory coeliac disease === About 1.5% of those with coeliac disease develop refractory coeliac disease (RCD), which is the persistence of symptoms of malabsorption and villous atrophy despite at least one year of the GFD. RCD has a high mortality and morbidity rate, is associated with more severe symptoms and is more common in older individuals (50<). Those with RCD are often referred to specialists and the diagnostic process usually includes monitoring compliance with the GFD, confirming the initial diagnoses of coeliac disease, and excluding alternative explanations for small intestine damage such as Crohn's disease, peptic duodenitis, small intestinal bacterial overgrowth, hypogammaglobulinemia, common variable immunodeficiency, autoimmune enteropathy, tropical sprue, collagenous sprue, and eosinophilic enteritis. There are two subtypes of RCD, type 1 and type 2. Biopsies of the duodenum and analysis of the intraepithelial lymphocytes in the duodenum are required to distinguish between the two types. Type 2 RCD is characterised by abnormal T cells in the small intestine; these findings are absent in type 1 RCD. In type 2 RCD, healthy lymphocytes are replaced by abnormal lymphocytes, increasing the risk of complications such as enteropathy-associated T-cell lymphoma (EATL), severe malabsorption, and ulcerative jejunoileitis, and results in poorer outcomes. Type 1 RCD is treated with steroids, azathioprine, and budesonide. The treatment of type 2 RCD is more complicated as it often does not improve with steroids, and azathioprine may increase the risk of EATL.
, gives an indication of how incompatible the two blocks are and whether they will microphase separate. For example, a diblock copolymer of symmetric composition will microphase separate if the product
Sources: en.wikipedia.org
cytology The study of the morphology, processes, and life history of living cells, particularly by means of light and electron microscopy. The term is also sometimes used as a synonym for the broader field of cell biology.
If a mutation is present in a germ cell, it can give rise to offspring that carries the mutation in all of its cells. This is the case in hereditary diseases. In particular, if there is a mutation in a DNA repair gene within a germ cell, humans carrying such germline mutations may have an increased risk of cancer. A list of 34 such germline mutations is given in the article DNA repair-deficiency disorder. An example of one is albinism, a mutation that occurs in the OCA1 or OCA2 gene. Individuals with this disorder are more prone to many types of cancers, other disorders and have impaired vision. DNA damage can cause an error when the DNA is replicated, and this error of replication can cause a gene mutation that, in turn, could cause a genetic disorder. DNA damages are repaired by the DNA repair system of the cell. Each cell has a number of pathways through which enzymes recognize and repair damages in DNA. Because DNA can be damaged in many ways, the process of DNA repair is an important way in which the body protects itself from disease. Once DNA damage has given rise to a mutation, the mutation cannot be repaired.
Previous forensic techniques employed for the organic analysis of lipsticks by compositional comparison include thin layer chromatography (TLC), gas chromatography (GC), and high-performance liquid chromatography (HPLC). These methods provide useful information regarding the identification of lipsticks. However, they all require long sample preparation times and destroy the sample. Nondestructive techniques for the forensic analysis of lipstick smears include UV fluorescence observation combined with purge-and-trap gas chromatography, microspectrophotometry and scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS), and Raman spectroscopy.
Sources: en.wikipedia.org
== Further reading == Adams E (1954). "Enzymatic synthesis of histidine from histidinol". J. Biol. Chem. 209 (2): 829–846. doi:10.1016/S0021-9258(18)65512-7. PMID 13192138. Adams E (1955). "L-Histidinal, a biosynthetic precursor of histidine". J. Biol. Chem. 217 (1): 325–344. doi:10.1016/S0021-9258(19)57184-8. PMID 13271397. Yourno J, Ino I (1968). "Purification and crystallization of histidinol dehydrogenase from Salmonella typhimurium LT-2". J. Biol. Chem. 243 (12): 3273–6. doi:10.1016/S0021-9258(18)93303-X. PMID 4872177. Loper JC (1968). "Histidinol dehydrogenase from Salmonella typhimurium Crystallization and composition studies". J. Biol. Chem. 243 (12): 3264–72. doi:10.1016/S0021-9258(18)93302-8. PMID 4872176.
=== Stable interactions vs. transient interactions === Stable interactions involve proteins that interact for a long time, taking part of permanent complexes as subunits, in order to carry out functional roles. These are usually the case of homo-oligomers (e.g. cytochrome c), and some hetero-oligomeric proteins, as the subunits of ATPase. On the other hand, a protein may interact briefly and in a reversible manner with other proteins in only certain cellular contexts – cell type, cell cycle stage, external factors, presence of other binding proteins, etc. – as it happens with most of the proteins involved in biochemical cascades. These are called transient interactions. For example, some G protein–coupled receptors only transiently bind to Gi/o proteins when they are activated by extracellular ligands, while some Gq-coupled receptors, such as muscarinic receptor M3, pre-couple with Gq proteins prior to the receptor-ligand binding. Interactions between intrinsically disordered protein regions to globular protein domains (i.e. MoRFs) are transient interactions.
Thus, truly comprehensive or 'deep' proteome analyses must assess proteoforms. There are two general approaches to proteome analysis - bottom up (BUP or shotgun) and top down (TDP). The former, a peptide-centric or proteogenomic approach, infers (often with quite limited data) the identities of canonical protein sequences by correlation with existing databases, mostly derived from genome sequencing projects. In contrast, TDP can, in theory, yield comprehensive proteome analyses at the level of proteoforms provided the methods used effectively address the full breadth of species in a proteome.
Sources: en.wikipedia.org
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.
Dry lyophilised powder is normally kept frozen and protected from moisture and light. Dissolved material is handled cold and used promptly to limit degradation.
It is not licensed as a medicine in major markets and is distributed as a research chemical. Sports organisations prohibit its use, and some countries restrict import and supply.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.